Priscilla A. Merriam

Priscilla A. Merriam

Hematology Oncology | Hematology | Oncology
450 Brookline Avenue
Boston, MA 02115

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications

Patterns of Response to Immune Checkpoint Inhibitors in Sarcomas With High Tumor Burden and/or Mismatch Repair Deficiency.

Patterns of Response to Immune Checkpoint Inhibitors in Sarcomas With High Tumor Burden and/or Mismatch Repair Deficiency.

Journal: JCO precision oncology
Published: July 06, 2026

Atezolizumab for Alveolar Soft Part Sarcoma: A Clinical Trial Update.

Atezolizumab for Alveolar Soft Part Sarcoma: A Clinical Trial Update.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 18, 2026

Epigenetic dysregulation of metabolic programs mediates liposarcoma cell plasticity.

Epigenetic dysregulation of metabolic programs mediates liposarcoma cell plasticity.

Journal: Science translational medicine
Published: January 21, 2026

A Phase 2 Study of Eribulin in Patients with Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma.

A Phase 2 Study of Eribulin in Patients with Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 04, 2025

Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trial.

Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trial.

Journal: Nature medicine
Published: June 27, 2025

Frequency and clinical features of germline pathogenic variants in sarcoma: a case-control study.

Frequency and clinical features of germline pathogenic variants in sarcoma: a case-control study.

Journal: Journal of the National Cancer Institute
Published: March 24, 2025

Epigenetic dysregulation of metabolic programs mediates liposarcoma cell plasticity.

Epigenetic dysregulation of metabolic programs mediates liposarcoma cell plasticity.

Journal: bioRxiv : the preprint server for biology
Published: February 03, 2025

Safety and Efficacy of the Combination Lurbinectedin plus Doxorubicin from a Phase 1b Trial in Patients with Advanced/Metastatic Soft-Tissue Sarcoma.

Safety and Efficacy of the Combination Lurbinectedin plus Doxorubicin from a Phase 1b Trial in Patients with Advanced/Metastatic Soft-Tissue Sarcoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 04, 2024

Image-guided percutaneous ablation of hepatic epithelioid hemangioendothelioma.

Image-guided percutaneous ablation of hepatic epithelioid hemangioendothelioma.

Journal: Abdominal radiology (New York)
Published: October 16, 2023

Atezolizumab for Advanced Alveolar Soft Part Sarcoma.

Atezolizumab for Advanced Alveolar Soft Part Sarcoma.

Journal: The New England journal of medicine
Published: September 06, 2023

SAR-096: Phase II Clinical Trial of Ribociclib in Combination with Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS).

SAR-096: Phase II Clinical Trial of Ribociclib in Combination with Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS).

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 21, 2023

Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates.

Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 02, 2023
Showing 1-12 of 24

Last Updated: 09/26/2026